GCG and chronic kidney disease: If further data reveal that GLP1-RA combination therapy is more effective in reducing UACR than GLP1-RA monotherapy or insulin therapy, GLP1-RA combination therapy could be the first line of glycemic control and renoprotection in diabetic patients at risk of progression to CKD.